Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women's Health Portfolio

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Organon & Co. is placed fourth among them.

Organon & Co. (NYSE:OGN) is a pharmaceutical company focused on women’s health and biosimilars. In Q2 2025, the company reported $1.594 billion in revenue and an adjusted EPS of $1.00, slightly exceeding market expectations. Despite a modest year-over-year revenue decline, the company raised its full-year 2025 revenue guidance to $6.275–$6.375 billion, reflecting confidence in recovery driven by new product launches and biosimilar expansion.

Organon & Co. (NYSE:OGN) is actively managing its debt profile, aiming to reduce net leverage below 4.0x by the end of 2025 and further to 3.5x by 2026, while implementing cost-saving measures to increase operational flexibility. For investors searching for overlooked stocks with turnaround potential, OGN’s progress in strengthening its balance sheet and advancing its portfolio makes it a compelling case. Key portfolio developments include VTAMA (tapinarof) cream, which is advancing in market access, and biosimilars expected to offset losses from legacy drugs like Atozet in Europe.

Organon & Co. (NYSE:OGN)’s strategy emphasizes innovation in women’s health and biosimilars to counter competitive and regulatory pressures. CEO Kevin Ali’s recent stock purchase highlights confidence in the business’s trajectory.

While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.